# A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

> **NCT00196716** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 21 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **BIOLOGICAL:** Fabrazyme (agalsidase beta)

## Key facts

- **NCT ID:** NCT00196716
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2006-04
- **Final completion:** 2007-03
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2015-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00196716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00196716, "A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00196716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*